Alida Biosciences Partners with Baylor College of Medicine
Alida Biosciences, a leader in next-generation RNA modification analysis, is excited to announce its inaugural service provider collaboration with the Genomic and RNA Profiling (GARP) Core at Baylor College of Medicine. This partnership marks a significant milestone in their mission to enhance RNA analysis capabilities, enabling groundbreaking research and diagnostics.
Introducing the EpiPlex™ Platform
The collaboration revolves around AlidaBio's EpiPlex™ Platform, the first comprehensive solution designed to detect and quantify multiple RNA modifications alongside gene expression through short-read sequencing. This platform, launched earlier this year, integrates the EpiPlex RNA Library Prep Kit with the EpiScout™ Analysis Suite, creating a unified workflow that reveals the functional implications of RNA modifications across various fields, including development and disease research.
Core Benefits of the Partnership
This partnership with Baylor's GARP Core is expected to broaden access to advanced transcriptomic profiling technologies. Dr. Gudrun Stengel, CEO of AlidaBio, expressed enthusiasm about working with such a prestigious institution. She stated, "This collaboration will empower researchers from various disciplines to utilize our innovative technology, fostering significant advancements in RNA biology."
Enhancing Research Capabilities
Dr. Daniel Kraushaar, the Director of the GARP Core, highlighted the importance of this technology in RNA biology. He noted that the EpiPlex platform allows researchers to investigate both gene expression and RNA modifications simultaneously, offering remarkable insights into post-transcriptional regulation. This access is vital for the Baylor research community and will also benefit researchers beyond the institution.
High Sensitivity and Versatility
Designed for clinical and translational research, the EpiPlex Kit is particularly effective for samples with limited RNA input. It can operate efficiently even with as little as 50 ng of total RNA, yielding high-resolution results from samples which are typically challenging, such as tissue biopsies and FFPE samples.
Streamlined Data Analysis
The accompanying EpiScout Analysis Suite is a user-friendly platform that automates the analysis and visualization of complex epitranscriptomic data. By merging RNA modification data with expression profiles, researchers can achieve a comprehensive understanding of transcriptome regulation, sidestepping the common issues associated with bioinformatics.
Future Developments for the EpiPlex Platform
The EpiPlex assay is designed to be automated and efficient, allowing laboratories to complete the wet-lab parts of their research in just one day. It is available in both 8- and 24-sample formats, making it ideal for labs of any size. Preliminary studies with early-access partners in academia and industry have confirmed the platform’s reliability and potential for extensive collaborative studies.
Looking ahead, AlidaBio plans to enhance the EpiPlex platform further, aiming to support even more RNA modification targets and higher resolution analysis. Plans also include developing targeted panels specifically designed for drug discovery and applications in disease research.
Learn More About Alida Biosciences
For those interested in exploring AlidaBio's products and capabilities, additional information is available on their official website.
About Alida Biosciences
Founded in 2020, Alida Biosciences is at the forefront of transforming epigenomics through user-friendly tools for comprehensive RNA modification analysis. Their innovative technologies are paving the way for concurrent detection and quantification of RNA modifications from clinically relevant samples, driving advancements in research, therapeutic methods, and diagnostics. AlidaBio is proud to be supported by several venture capital partners and SBIR grants from the NHGRI.
Frequently Asked Questions
What is the primary technology introduced by Alida Biosciences?
Alida Biosciences has introduced the EpiPlex™ Platform, which enables simultaneous detection and quantification of RNA modifications and gene expression.
What institution is Alida collaborating with?
Alida is partnering with the GARP Core at Baylor College of Medicine to enhance RNA sequencing and analysis capabilities.
What are the benefits of the EpiPlex Platform?
The EpiPlex Platform offers high sensitivity for limited RNA samples and integrates multiple RNA modifications with gene expression data for deeper insights.
How does the EpiScout Analysis Suite assist researchers?
The EpiScout Analysis Suite automates the complex data analysis and visualization processes, making it easier for researchers to work with epitranscriptomic data.
What are AlidaBio's future plans for the EpiPlex platform?
AlidaBio aims to expand the platform to include more RNA modification targets and develop specialized panels for drug discovery and disease applications.
